FY2025 · ended Dec 31, 2025 · Revenue $52.84M, +9.9% YoY · Filed Mar 10, 2026
Apyx Medical Corp (APYX) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $52.8 million and a net loss of $11.2 million. Free cash flow was -$9.1 million. As of Jun 30, 2026 it held $27.6 million in cash and investments and $41.8 million in total debt.
Revenue (TTM)
$58.41M
+25.6% vs year-ago TTM
Net income (TTM)
$-8.63M
+50.0% vs year-ago TTM
Operating cash flow (TTM)
$-10.13M
-8.8% vs year-ago TTM
Free cash flow (TTM)
$-11.05M
-10.1% vs year-ago TTM
EPS
$-0.54
+19.4% vs prior year
Dividend per share
None
Shares outstanding
41.83M
+10.7% vs prior year
Net cash
$-14.19M
as of Jun 30, 2026
Operating margin
-6.1%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- APYX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Clearwater, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 719135
- Former names
- BOVIE MEDICAL CORP (until Jan 2, 2019); BOVIE MEDICAL Corp (until Jan 2, 2019); AN CON GENETICS INC (until Jan 13, 1999)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $52.8M | $48.1M | $52.3M | $44.5M | $48.5M |
| Operating income | -$6.4M | -$18.8M | -$17.3M | -$23.6M | -$14.4M |
| Net income | -$11.2M | -$23.5M | -$18.7M | -$23.2M | -$15.2M |
| Diluted EPS | — | — | -$0.54 | -$0.67 | -$0.44 |
| Operating cash flow | -$8.0M | -$18.0M | -$5.2M | -$20.3M | -$10.4M |
| Free cash flow | -$9.1M | -$18.8M | -$5.8M | -$21.3M | -$11.2M |
| Total assets | $66.8M | $64.8M | $79.2M | $51.8M | $68.7M |
| Total liabilities | $52.0M | $50.5M | $52.3M | $14.0M | $14.7M |
| Stockholders' equity | $14.5M | $14.2M | $26.7M | $37.6M | $53.7M |
| Cash and investments | $31.7M | $31.7M | $43.7M | $10.2M | $30.9M |
| Total debt | $42.0M | $42.4M | $38.5M | $796,000 | $305,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Other events
|
Sep 29, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Aug 7, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
All 992 Apyx Medical Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.